Articles tagged with 'Export-IR' | Bayer

Newsroom Bayer (Export-IR)

2022
September
08,
2022
| 14:59 PM Europe/Amsterdam
Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibe...
Read more
September
02,
2022
| 10:15 AM Europe/Amsterdam
U.S. Food and Drug Administration (FDA) granted label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes...
Read more
September
01,
2022
| 16:00 PM Europe/Amsterdam
Succeeds Fei-Fei Li, who stepped down at the end of August...
Read more
August
28,
2022
| 09:14 AM Europe/Amsterdam
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-ris...
Read more
August
12,
2022
| 11:20 AM Europe/Amsterdam
Leverkusen, August 12, 2022 – Bayer welcomes the dismissal of BASF’s claims by the arbitral tribunal. Bayer provided adequate information on the cost structure of the seeds businesses acquired by BASF in August 2018 and did not breach any contractual...
Read more
August
11,
2022
| 14:00 PM Europe/Amsterdam
Following strong second quarter results, Bayer’s Fields of Opportunity Technology Showcase highlights cutting-edge technologies and pipeline solutions expected to propel farmer productivity, sustainability, and company growth / Featured breakthrough ...
Read more
August
08,
2022
| 08:30 AM Europe/Amsterdam
Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) / Today’s approval under the FDA’s Re...
Read more
August
04,
2022
| 07:30 AM Europe/Amsterdam
Group sales increase by 9.6 percent (Fx & portfolio adj.) to 12.819 billion euros / EBITDA before special items rises by 30.0 percent to 3.349 billion euros / Crop Science and Consumer Health achieve strong sales and earnings growth / Pharmaceuticals...
Read more
August
01,
2022
| 16:00 PM Europe/Amsterdam
Investment delivers on Bayer’s commitments to sustainability and may help decarbonize agriculture and reduce reliance on nitrogen fertilizer with combined expertise of existing investors, Bunge and Chevron / Growers to gain new revenue streams throug...
Read more
July
14,
2022
| 08:00 AM Europe/Amsterdam
Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022...
Read more
June
30,
2022
| 08:30 AM Europe/Amsterdam
Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure and premature death / Kerendia™ (finerenone) is the first non-steroidal, selective mineralocorticoid rece...
Read more
June
29,
2022
| 14:00 PM Europe/Amsterdam
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovat...
Read more
June
28,
2022
| 14:00 PM Europe/Amsterdam
AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity / Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow / Market introduction t...
Read more
June
08,
2022
| 08:00 AM Europe/Amsterdam
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities / Acceleration of the development of cell therapies in BlueRock’s pipeline, with initial focus on the ongoing BRT-DA01 clinical tri...
Read more
May
23,
2022
| 16:39 PM Europe/Amsterdam
Data from the exploratory post hoc analysis of FIDELITY also highlight the potential of Kerendia™ (finerenone) to reduce the incidence of hospitalization for heart failure (HHF), with a more pronounced effect in patients with left ventricular hypertr...
Read more
May
19,
2022
| 10:00 AM Europe/Amsterdam
Studied in adults with symptomatic chronic heart failure and reduced ejection fraction who are stabilized after a recent decompensation event with IV therapy / Approved in China to reduce the risk of heart failure (HF) hospitalization or the need for...
Read more
May
10,
2022
| 07:30 AM Europe/Amsterdam
Group sales grow by 14.3 percent (Fx & portfolio adj.) to 14.639 billion euros / EBITDA before special items increases by 27.5 percent to 5.251 billion euros / Substantial sales and earnings growth at Crop Science and Consumer Health / Sales up sligh...
Read more
May
03,
2022
| 14:00 PM Europe/Amsterdam
Application is being reviewed concurrently among participating international health authorities under the FDA Oncology Center of Excellence’s (OCE) Project Orbis initiative...
Read more
April
29,
2022
| 10:00 AM Europe/Amsterdam
Operationally and strategically successful in 2021 / Dividend of 2.00 euros per share proposed / Very successful start to 2022...
Read more
April
22,
2022
| 10:30 AM Europe/Amsterdam
Submission to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for an additional indication in patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Submission based on data from the pivota...
Read more
April
13,
2022
| 08:40 AM Europe/Amsterdam
Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors in adult and pediatric patients in China / In clinical studies of patients with TRK fusion solid tumors, laro...
Read more
April
03,
2022
| 18:15 PM Europe/Amsterdam
Data from the PACIFIC-AF trial demonstrated lower observed rates of ISTH major and clinically relevant non-major bleeding for asundexian (a FXIa inhibitor) compared with apixaban in patients with atrial fibrillation at risk of stroke / The data, simu...
Read more
April
01,
2022
| 13:00 PM Europe/Amsterdam
Bayer to invest more than 1.3 billion euros over the next three years in its impact investment unit Leaps by Bayer / Focus on leading pharmaceutical technology platforms such as Cell & Gene Therapy to deliver solutions to patients in areas of high un...
Read more
March
28,
2022
| 09:00 AM Europe/Amsterdam
Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure or premature death / Kerendia™ (finerenone) is the first non-steroidal, selective mineralocorticoid recep...
Read more
March
22,
2022
| 19:30 PM Europe/Amsterdam
New issue of two tranches with a non-call period of 5.5 and 8.5 years, respectively, combined with a tender offer for one of Bayer’s existing hybrid bonds...
Read more
March
11,
2022
| 07:30 AM Europe/Amsterdam
Submission to the Ministry of Health, Labor and Welfare (MHLW) in Japan for an additional indication of darolutamide in prostate cancer with distant metastases / Application is based on data from the pivotal Phase III ARASENS trial, in which the use ...
Read more
March
10,
2022
| 07:30 AM Europe/Amsterdam
Transaction streamlines Crop Science portfolio and ensures greater focus on core agricultural business / Cinven seeks to continue to drive innovation and accelerate growth through significant investment in the acquired business...
Read more
March
09,
2022
| 07:30 AM Europe/Amsterdam
Submissions in the U.S. and European Union (EU) for an additional indication in patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Submissions are based on data from the pivotal Phase III ARASENS trial recently published in The New ...
Read more
March
01,
2022
| 07:30 AM Europe/Amsterdam
Group sales increase by 8.9 percent (Fx & portfolio adj.) to 44.081 billion euros / EBITDA before special items declines by 2.5 percent to 11.179 billion euros - inflation-related increase in costs and negative currency effects largely offset / Crop ...
Read more
February
24,
2022
| 08:30 AM Europe/Amsterdam
There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / The Phase II CONFIDENCE study will investigate the effect of the ...
Read more